Nanjing Wanrong Jiancheng Pharmaceutical Technology

Nanjing Wanrong Jiancheng Pharmaceutical Technology is a clinical-stage biotechnology company based in Nanjing, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company primarily focuses on metabolic disorders, with a specialized emphasis on treating hyperuricemia and gout. Its lead candidate, WR-101, is a highly selective URAT1 inhibitor currently undergoing Phase 2 clinical trials to evaluate its efficacy in lowering serum uric acid levels. Beyond its internal drug development pipeline, the company provides pharmaceutical technology services, including R&D consulting and technology transfer. Nanjing Wanrong Jiancheng leverages its location in the Nanjing Economic and Technological Development Zone to collaborate with regional academic institutions and industry partners.